Exocrine pancreatic insufficiency and hyperoxaluria: a preventable renal complication from gastroenterology

Authors

DOI:

https://doi.org/10.47892/rgp.2026.461.2078

Keywords:

Exocrine Pancreatic Insufficiency, Hyperoxaluria, Kidney Diseases, Oxalates

Abstract

Exocrine pancreatic insufficiency (EPI) is the inability of the pancreas to produce essential digestive enzymes for fat metabolism, leading to systemic and nutritional repercussions. Although its manifestations are typically digestive, systemic complications such as enteric hyperoxaluria can occur. We present a 68-year-old man with insulin-dependent diabetes mellitus, who developed steatorrheic diarrhea and significant weight loss. Computed tomography revealed an atrophic pancreas with diffuse calcifications. Based on a diagnosis of chronic pancreatitis, pancreatic enzyme replacement therapy (PERT) was initiated empirically with clinical improvement. Three years later, while asymptomatic from a gastrointestinal perspective, he developed bilateral calcium oxalate nephrolithiasis progressing to end-stage renal disease, requiring hemodialysis. This was interpreted as oxalate nephropathy secondary to enteric hyperoxaluria, favored by suboptimal PERT dosing and poor follow-up adherence. PERT was optimized to 40,000 units per meal with good nutritional and digestive outcomes. The etiological study for EPI showed no obstructive or systemic causes. This case highlights the importance of suspecting EPI when systemic complications like secondary hyperoxaluria appear. Early diagnosis remains challenging and requires close monitoring, as specific guidelines to prevent irreversible renal damage are lacking; early recognition can significantly improve prognosis and quality of life.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Whitcomb DC, Buchner AM, Forsmark CE. AGA Clinical Practice Update on the Epidemiology, Evaluation, and Management of Exocrine Pancreatic Insufficiency: Expert Review. Gastroenterology. 2023;165(5):1292-301. doi: 10.1053/j.gastro.2023.07.007.

Lewis D. An Updated Review of Exocrine Pancreatic Insufficiency Prevalence finds EPI to be More Common in General Population than Rates of Co-Conditions. J Gastrointestin Liver Dis. 2024;33(1):123-30. doi: 10.15403/jgld-5005.

Capurso G, Traini M, Piciucchi M, Signoretti M, Arcidiacono PG. Exocrine pancreatic insufficiency: Prevalence, diagnosis, and management. Clin Exp Gastroenterol. 2019;12:129-139. doi: 10.2147/CEG.S168266.

Hwang HJ, Petruzzi ML, Gutiérrez S, Fuxman C, Nachman F. La insuficiencia pancreática exocrina: estado actual de su conocimiento entre los profesionales de Argentina. Acta Gastroenterol Latinoam. 2020;50(4):431-8.

Chen T, Qian B, Zou J, Luo P, Zou J, Li W, et al. Oxalate as a potent promoter of kidney stone formation. Front Med (Lausanne). 2023;10:1159616. doi: 10.3389/fmed.2023.1159616.

Demoulin N, Issa Z, Crott R, Morelle J, Danse E, Wallemacq P, et al. Enteric hyperoxaluria in chronic pancreatitis. Medicine (Baltimore). 2017;96(19):e6758. doi: 10.1097/ MD.0000000000006758.

Baltazar P, de Melo Junior AF, Fonseca NM, Lança MB, Faria A, Sequeira CO, et al. Oxalate (dys)Metabolism: Person-to-Person Variability, Kidney and Cardiometabolic Toxicity. Genes (Basel). 2023;14(9):1719. doi: 10.3390/genes14091719.

Dominguez-Muñoz JE, Vujasinovic M, de la Iglesia D, Cahen D, Capurso G, Gubergrits N, et al. European guidelines for the diagnosis and treatment of pancreatic exocrine insufficiency: UEG, EPC, EDS, ESPEN, ESPGHAN, ESDO, and ESPCG evidencebased recommendations. United European Gastroenterol J. 2025;13(1):125-72. doi: 10.1002/ueg2.12674.

Buysschaert B, Aydin S, Morelle J, Gillion V, Jadoul M, Demoulin N. Etiologies, Clinical Features, and Outcome of Oxalate Nephropathy. Kidney Int Rep. 2020;5(9):1503-1509. doi: 10.1016/j.ekir.2020.06.021.

Tilia R, Kojc N, Škoberne A. Secondary oxalate nephropathy in a patient with exocrine pancreatic insufficiency successfully treated, with complete kidney recovery. Clin Nephrol. 2021;96(1):62-67. doi: 10.5414/CNP96S11.

Domínguez-Muñoz JE. Pancreatic exocrine insufficiency: Diagnosis and treatment. J Gastroenterol Hepatol. 2011;26(s2):12-6. doi: 10.1111/j.1440-1746.2010.06600.x.

De Martines D, Gianotten S, Wetzels J, Van der Meijden W. Secondary hyperoxaluria due to pancreatic insufficiency. Neth J Med. 2019;77(08):287-92.

Roodnat JI, de Mik-van Egmond AME, Visser WJ, Berger SP, van der Meijden WAG, Knauf F, et al. A Successful Approach to Kidney Transplantation in Patients With Enteric (Secondary) Hyperoxaluria. Transplant Direct. 2017;3(12):e331. doi: 10.1097/TXD.0000000000000748.

Quintero E, Bird VY, Liu H, Stevens G, Ryan AS, Buzzerd S, et al. A Prospective, Double-Blind, Randomized, PlaceboControlled, Crossover Study Using an Orally Administered Oxalate Decarboxylase (OxDC). Kidney360. 2020;1(11):1284- 1290. doi: 10.34067/KID.0001522020.

Liu H feng, Li C yan, Liu Y hong, Yao Q, Li Q shan, Yu LJ. OxDc-A0: an oral gastro-tolerant oxalate decarboxylase for treating secondary hyperoxaluria. Urolithiasis. 2025;53(1):47. doi: 10.1007/s00240-025-01698-0.

Published

03/29/2026

How to Cite

1.
Hornung E, Moratorio I, Amor S, Seija M, Canavesi A. Exocrine pancreatic insufficiency and hyperoxaluria: a preventable renal complication from gastroenterology. Rev Gastroenterol Peru [nternet]. 2026 Mar. 29 [cited 2026 Apr. 1];46(1):78-81. vailable from: https://revistagastroperu.com/index.php/rgp/article/view/2078

Issue

Section

REPORTES DE CASOS